Fig. 2

Schematic representation showing the activation of RTK-RAS signaling pathway by 22 gene fusions in our colorectal carcinoma cohort. All of the detected gene rearrangements within NTRK1, NTRK3, ALK, RET, MET, BRAF and MAPK1 are targetable with currently available small molecule kinase inhibitors